Holen Sie sich die Stockscreener-App
12.41
1.80%
0.22
Handel nachbörslich:
12.01
-0.40
-3.22%
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EyePoint Pharmaceuticals Inc - TradingKey
EyePoint, Inc. Revenue Breakdown – NASDAQ:EYPT - TradingView
EYPT|EyePoint Pharmaceuticals Inc|Price:12.190|Chg%:-0.280 - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RBC Capital Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
J.P. Morgan Maintains EyePoint(EYPT.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
EYPT (NASDAQ: EYPT) plans sale of 1,235 common shares from options - Stock Titan
EYPT (NASDAQ: EYPT) affiliate plans sale of 1,235 common shares via Form 144 - Stock Titan
Form 144 EyePoint For: 21 July By Investing.com - Investing.com South Africa
EYPT (NASDAQ: EYPT) plans brokered sale of 421,235 shares valued at $5.5M - Stock Titan
Price to earnings forward of EyePoint, Inc. – MUN:PV3B - TradingView
Drug company to pay $4.7M after admitting it paid providers to use its product - Yahoo Finance
Watertown Company Will Pay Nearly $4.7 Million to Resolve False Claims Act Allegations - watertownmanews.com
EyePoint to pay $4.6M to settle with DOJ over kickback claims - MSN
EyePoint Pharmaceuticals Agrees to Pay $4.6 Million to Settle False Claims Act Allegations - Markets Herald
EyePoint, Inc. Settles DOJ False Claims Act Case and Implements Comprehensive Compliance Program - Minichart
Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily
EyePoint Pharmaceuticals Agrees to Settle US False Claims Act Allegations - Moomoo
EyePoint to Pay $4.7M to Resolve Allegations of False Claims Act Violations - Moomoo
Eyepoint Enters Settlement Agreement With DOJ, OIG-HHS, And DHASEC Filing - TradingView
EyePoint Pharmaceuticals (EYPT) Settles for $4.6M Over Kickback Allegations - GuruFocus
EyePoint (NASDAQ: EYPT) signs five-year federal Corporate Integrity Agreement - Stock Titan
United States: EyePoint Pharmaceuticals To Pay $4.6 Million To Resolve False Claims Act Allegations - The St Kitts Nevis Observer
EyePoint Agrees To Pay $4.65M To U.S. Government In FCA Suit Settlement - Mealey's
EyePoint to pay $4.6M to settle with DoJ over kickback claims - Seeking Alpha
Stifel Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
EYPT Initiated Coverage by Stifel -- Buy Rating with $40 Price T - GuruFocus
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Two New EyePoint Employees Receive Options for 63,500 Shares - Stock Titan
Stifel initiates EyePoint stock with buy rating on retinal drug potential By Investing.com - Investing.com South Africa
Stifel initiates EyePoint stock with buy rating on retinal drug potential - Investing.com Nigeria
Stifel Initiates EyePoint(EYPT.US) With Buy Rating, Announces Target Price $40 - Moomoo
EyePoint, Inc. (EYPT) CEO exercises RSUs, with shares withheld for taxes - Stock Titan
Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
EyePoint Names Tarek S. Hassan, MD, as SVP and Chief Strategic Science Officer - VisionMonday.com
Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
EyePoint Appoints Retina Specialist Tarek S. Hassan as Chief Strategic Science Officer - citybiz
EyePoint Appoints Retina Specialist Dr. Tarek S. Hassan as Chief Strategic Science Officer - Quiver Quantitative
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer - marketscreener.com
Renowned retina specialist Tarek S. Hassan joins EyePoint ahead of key DURAVYU trial readout - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base? - simplywall.st
ETFs Investing in EyePoint, Inc. Stocks - TradingView
EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances - AD HOC NEWS
EyePoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight - Moomoo
EYPT Assumed by Cantor Fitzgerald -- Rating Overweight with PT a - GuruFocus
Price to sales forward of EyePoint, Inc. – FWB:PV3B - TradingView
Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks - Yahoo Finance
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):